Royal Bank of Canada set a €130.00 ($151.16) target price on MorphoSys (ETR:MOR) in a research note released on Friday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
A number of other research firms have also recently issued reports on MOR. Deutsche Bank set a €133.00 ($154.65) price target on MorphoSys and gave the stock a buy rating in a report on Thursday. JPMorgan Chase & Co. set a €120.00 ($139.53) price target on MorphoSys and gave the stock a buy rating in a report on Wednesday. Berenberg Bank set a €150.00 ($174.42) price target on MorphoSys and gave the stock a buy rating in a report on Monday, August 5th. Goldman Sachs Group set a €114.00 ($132.56) price target on MorphoSys and gave the stock a neutral rating in a report on Wednesday. Finally, Independent Research set a €96.00 ($111.63) price target on MorphoSys and gave the stock a neutral rating in a report on Thursday, July 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. MorphoSys currently has an average rating of Hold and a consensus price target of €113.56 ($132.04).
Shares of MorphoSys stock traded down €1.60 ($1.86) on Friday, reaching €111.00 ($129.07). 141,604 shares of the company’s stock were exchanged, compared to its average volume of 153,687. The firm has a market cap of $3.50 billion and a P/E ratio of -59.74. MorphoSys has a 52 week low of €76.45 ($88.90) and a 52 week high of €111.00 ($129.07). The business has a 50-day moving average price of €96.61. The company has a quick ratio of 7.53, a current ratio of 7.75 and a debt-to-equity ratio of 8.65.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Further Reading: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.